Itacitinib (BioDeep_00000797296)
代谢物信息卡片
化学式: C26H23F4N9O (553.1961596)
中文名称: 伊他替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F
InChI: InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D10944
- PubChem: 53380437
- DrugBank: DB12154
- ChEMBL: CHEMBL3622820
- CAS: 1651228-00-0
- CAS: 1334298-90-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Journal for immunotherapy of cancer.
2022 03; 10(3):. doi:
10.1136/jitc-2021-004223. [PMID: 35288468] - Jacob M Rosenberg, Joshua M Peters, Travis Hughes, Caleb A Lareau, Leif S Ludwig, Lucas R Massoth, Christina Austin-Tse, Heidi L Rehm, Bryan Bryson, Yi-Bin Chen, Aviv Regev, Alex K Shalek, Sarah M Fortune, David B Sykes. JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia.
Med (New York, N.Y.).
2022 Jan; 3(1):42-57.e5. doi:
10.1016/j.medj.2021.12.003. [PMID: 35590143] - April M Barbour, Kevin Rockich, Evan Cimino, Gongfu Zhou, Caterina Leonetti-Whalen, Xuejun Chen, Swamy Yeleswaram, Noam Epstein, Naresh Punwani. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Journal of clinical pharmacology.
2021 07; 61(7):954-960. doi:
10.1002/jcph.1814. [PMID: 33434286] - Xiaohua Gong, Borje Darpo, Hongqi Xue, Naresh Punwani, Kevin He, April M Barbour, Noam Epstein, Robert Landman, Xuejun Chen, Swamy Yeleswaram. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Clinical pharmacology in drug development.
2020 08; 9(6):677-688. doi:
10.1002/cpdd.758. [PMID: 31821750] - Nithya Srinivas, April M Barbour, Noam Epstein, Gongfu Zhou, Susan Petusky, Zhinyin Xun, Brad Yuska, Thomas Marbury, Xuejun Chen, Swamy Yeleswaram, Naresh Punwani. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Journal of clinical pharmacology.
2020 08; 60(8):1022-1029. doi:
10.1002/jcph.1601. [PMID: 32149388]